Additionally, the prominent clinical manifestation of case 3 was epilepsy, which is reported in 95% of the SGS patients with hot spot mutations, and frequently observed also in patients with SETBP1 haploinsufficiency (3, 7). This evidence concerns the gene SETBP1 and epilepsy.